Does UnitedHealthcare Cover Vyleesi (Bremelanotide)?

What Is Vyleesi and Why Does Coverage Get Complicated?

Vyleesi (bremelanotide) is a melanocortin receptor agonist administered as a 1.75 mg subcutaneous auto-injector used as needed at least 45 minutes before anticipated sexual activity. The FDA approved it on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it only the second approved pharmacological treatment for this condition after flibanserin (Addyi). The full FDA prescribing information is available on the FDA website.

HSDD affects an estimated 8 to 10 percent of U.S. Women across all age groups, and its clinical definition requires that the low desire causes marked personal distress. Without that distress criterion, the diagnosis does not apply and insurers will deny claims outright.

Coverage is complicated because U.S. Commercial insurers historically treated sexual health drugs as "lifestyle" or "cosmetic" rather than medically necessary. That framing is slowly shifting, but UnitedHealthcare still gates access through a prior authorization process that many patients and prescribers find burdensome.

Bremelanotide vs. Flibanserin: Why the Drug Choice Affects Coverage

Flibanserin (Addyi) is a daily oral serotonin-norepinephrine reuptake modulator approved in 2015. Bremelanotide is an as-needed subcutaneous injection. Both treat HSDD in premenopausal women, but their mechanisms, dosing schedules, and insurer treatment hierarchies differ.

UHC often positions flibanserin as a preferred agent (step therapy) over bremelanotide, meaning a patient may need to document a trial of flibanserin before UHC will authorize Vyleesi. Clinicians can bypass that step if the patient has a contraindication to flibanserin, which include alcohol use or hepatic impairment.

The Clinical Evidence Base That Supports Coverage Arguments

The RECONNECT trials (two Phase 3 randomized controlled trials, combined N=1,267) evaluated bremelanotide versus placebo in premenopausal women with HSDD. Published in Obstetrics and Gynecology in 2019, the trials demonstrated a statistically significant improvement in the Female Sexual Function Index (FSFI) desire domain score and a reduction in Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score (personal distress related to low desire) at 24 weeks (P<0.001 for both co-primary endpoints). Read the full RECONNECT publication on PubMed.

That trial evidence is your prescriber's best tool when writing a letter of medical necessity for the prior authorization or appeal process.

UnitedHealthcare Formulary Placement for Vyleesi

Most UHC commercial PPO and HMO formularies place Vyleesi on Tier 3 (non-preferred brand) or a specialty tier, depending on the plan design. Tier placement directly determines your copay or coinsurance.

How to Find Your Specific Tier

UHC plan formularies are not universal. Tier placement varies across:

• Employer-sponsored self-funded plans (where the employer, not UHC, sets the drug benefit)
• Fully insured individual and small-group plans
• UHC Medicare Advantage plans (Vyleesi is generally not covered under Part D because Medicare does not cover drugs for sexual dysfunction)

To confirm your plan's tier, log into your UHC member portal at myuhc.com, click "Coverage and Benefits," then "Prescription Drug List." Enter the drug name "bremelanotide" or "Vyleesi." The results will display the tier and any coverage restrictions such as quantity limits.

Quantity Limits That Affect Out-of-Pocket Cost

Even when UHC approves Vyleesi, most plans cap dispensing at eight auto-injectors per 30-day supply. The FDA label states the drug should not be used more than once in 24 hours and no more than approximately eight times per month given its transient blood-pressure-elevating effect. That limit usually aligns with clinical guidance, but it is worth confirming the authorized quantity in the PA approval letter so there are no surprises at the pharmacy.

Prior Authorization Criteria for Vyleesi on UnitedHealthcare

Prior authorization (PA) is required on almost every UHC commercial plan. The prescribing clinician (typically a gynecologist, psychiatrist, or primary care provider) submits the PA request, but understanding the criteria helps patients prepare for the conversation.

Standard PA Requirements

UHC's clinical coverage guidelines for bremelanotide generally require documentation of all of the following:

1. Confirmed HSDD diagnosis. The chart must include use of a validated tool such as the FSDS-DAO or FSFI to confirm low desire that causes personal distress. A blanket note saying "low libido" is insufficient.
2. Premenopausal status. Bremelanotide's FDA approval is limited to premenopausal women. UHC will deny the claim if the patient is postmenopausal.
3. Ruling out reversible causes. The prescriber must document that thyroid disease, medication side effects (particularly SSRIs), relationship distress, and hormonal insufficiency have been evaluated. The Endocrine Society's clinical practice guideline on female sexual dysfunction supports this workup.
4. Prescriber specialty or documented training. Some UHC plans require that the prescribing clinician have documented experience in sexual medicine or women's health.
5. Step therapy with flibanserin or psychotherapy. See the section below.

How Prescribers Submit the PA

Most submissions go through the UHC electronic portal (UnitedHealthcare Link or Surescripts), or via phone to UHC's pharmacy benefit line. PA decisions are typically returned within 72 hours for standard requests or 24 hours for urgent requests under NCQA standards.

Does UnitedHealthcare Require Step Therapy Before Vyleesi?

Yes, UHC applies step therapy on most commercial plans before approving Vyleesi. Step therapy means the patient must first try and fail (or have a contraindication to) one or more preferred agents.

First-Line Step: Flibanserin (Addyi)

Flibanserin is typically the required first-line agent. UHC generally requires documentation of one of the following:

• A minimum 8-week trial of flibanserin 100 mg nightly with inadequate response (defined as no clinically meaningful improvement in desire or distress scores)
• A documented contraindication: current alcohol use, use of moderate-to-strong CYP2C19 inhibitors (e.g., fluconazole, omeprazole), or hepatic impairment

If flibanserin is contraindicated, UHC may waive the step-therapy requirement entirely. The prescriber should document the contraindication explicitly in the PA submission rather than waiting for a denial and appealing.

Second-Line Step: Psychotherapy

Some UHC plans also require documented engagement in sex therapy or cognitive behavioral therapy targeting HSDD before approving bremelanotide. The American College of Obstetricians and Gynecologists (ACOG) does recommend that psychological interventions be considered alongside pharmacotherapy for HSDD. ACOG's Committee Opinion 213 on sexual dysfunction covers this.

If your plan requires this step, ask your prescriber to document any therapy you have attended and note that ongoing therapy will continue alongside the medication.

What Happens If UnitedHealthcare Denies Vyleesi?

A denial is not the end. UHC provides a structured appeal pathway, and a well-prepared appeal succeeds more often than most patients expect.

Level 1 Internal Appeal

File within 180 days of the denial notice. The appeal should include:

• A letter of medical necessity from the prescribing clinician citing the RECONNECT trial data and the patient's specific clinical history
• Completed FSFI or FSDS-DAO scores documented in the chart
• Evidence of flibanserin trial or contraindication
• A copy of UHC's own clinical coverage policy for bremelanotide, with the plan's criteria highlighted alongside documentation showing each criterion is met

UHC must issue a Level 1 decision within 30 days for pre-service appeals (15 days for urgent cases).

Level 2 Internal Appeal

If Level 1 is denied, file a Level 2 appeal with additional clinical support. Consider requesting a peer-to-peer (P2P) call between the prescribing physician and the UHC medical director reviewing the case. P2P calls resolve a meaningful share of specialty drug denials without escalation.

The HealthRX Clinical Access Team uses the following four-point framework when preparing Vyleesi appeals for our patients: (1) anchor the letter of medical necessity to the RECONNECT co-primary endpoint data with specific p-values; (2) include patient-completed validated scales dated within 90 days; (3) cite the specific UHC coverage policy number and version date to show the prescriber has reviewed the criteria; (4) request the peer-to-peer call simultaneously with the Level 2 filing rather than waiting for the written decision.

External Independent Review Organization (IRO)

If both internal appeal levels fail, you have the right under the Affordable Care Act and ERISA (for employer plans) to request external review by an independent review organization. The IRO's decision is binding on UHC. IRO approval rates for specialty drugs with strong phase 3 trial data tend to run higher than internal appeal approval rates, though exact figures vary by state and drug category.

File the external review request within four months of the final internal denial. Your state insurance commissioner's office can help identify the designated IRO.

UnitedHealthcare Vyleesi Coverage: Medicare and Medicaid

Medicare

Medicare Part D plans are prohibited by federal statute from covering drugs indicated exclusively for sexual dysfunction. Vyleesi falls into this exclusion. Medicare Advantage plans follow the same rule. If you are a Medicare beneficiary, you will need to pay cash or use manufacturer assistance programs regardless of your supplemental coverage.

Medicaid

Medicaid coverage varies by state. Federally, Medicaid is also not required to cover drugs for sexual dysfunction, and most state Medicaid programs exclude Vyleesi. A small number of states with expanded formularies may offer coverage with PA; check your state's Medicaid preferred drug list directly.

Out-of-Pocket Cost Without Approval and How to Reduce It

The list price of Vyleesi is approximately $1,200 per month for a package of four auto-injectors (roughly $300 per dose). If your PA is denied or pending, there are several ways to reduce cost.

Manufacturer Savings Card

AMAG Pharmaceuticals (now Palatin Technologies' commercial partner) offers a savings card for commercially insured patients who do not have a PA approval on file. Eligible patients may pay as little as $99 per month, depending on program availability. Federal law prohibits using manufacturer savings cards if you are covered by Medicare, Medicaid, or any other federal health care program. Confirm eligibility at the program's enrollment site before presenting the card at the pharmacy.

GoodRx and Specialty Pharmacy Cash Pay

GoodRx and similar discount platforms can bring the cash price below $1,000 at select specialty pharmacies, though prices fluctuate. Specialty pharmacies that compound similar peptides are not an equivalent alternative; bremelanotide is a protected FDA-approved drug and no compounded version has the same regulatory standing.

Patient Assistance Programs

AMAG's patient assistance program (PAP) may provide free or reduced-cost Vyleesi to uninsured or underinsured patients who meet income criteria (typically household income at or below 400 percent of the federal poverty level). Your prescriber's office or a HealthRX care coordinator can help with PAP enrollment paperwork.

How to Talk to Your Doctor About Getting Vyleesi Covered

The single most common reason PA requests fail is incomplete documentation. Your prescriber needs to submit a chart note that reads less like a routine visit summary and more like a clinical argument.

What a Strong PA Submission Looks Like

Ask your prescriber to include:

• Your baseline FSFI score (normal total score is 26.55; a score at or below 26.55 suggests female sexual dysfunction) and FSDS-DAO Item 13 score
• A timeline of how long you have experienced low desire and the associated distress
• A list of medications reviewed for sexual side-effect potential, especially SSRIs, antihypertensives, and oral contraceptives
• Thyroid function tests and relevant hormone levels (estradiol, testosterone if tested) with dates
• Documentation of any psychotherapy attended for this issue
• The reason flibanserin is inappropriate or was tried and failed, with dates

Timing Matters

Start the PA process before your first fill attempt. A pharmacy rejection generates a claim denial in UHC's system that can slow down the PA review. Ask the prescriber to submit the PA as part of the initial prescription workflow rather than after the pharmacy has already rejected the claim.

Clinical Context: Who Is Vyleesi Appropriate For?

Not every patient with low libido meets the clinical criteria for HSDD or for bremelanotide specifically. The drug is FDA-approved only for premenopausal women, and the label carries a boxed warning about transient blood pressure increases (mean systolic increase of 6.8 mmHg and diastolic increase of 4.9 mmHg within 12 hours of injection, per the RECONNECT safety data). See the full RECONNECT safety profile at PubMed.

Patients Who May Not Be Good Candidates

Bremelanotide should be used cautiously or avoided in women with:

• Uncontrolled hypertension (baseline systolic BP above 165 mmHg or diastolic above 95 mmHg)
• High cardiovascular risk given the transient BP effect
• Postmenopausal status (outside the approved indication)
• Current use of naltrexone (reduced bremelanotide exposure due to drug interaction)

The FSFI cutoff for clinical HSDD is frequently cited in the literature; a total score at or below 26.55 on the 19-item FSFI correlates with sexual dysfunction. See the FSFI validation study at PubMed.

Guideline Support

The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 process-of-care algorithm for HSDD lists bremelanotide as a first-line pharmacological option after appropriate evaluation, alongside flibanserin. That guideline endorsement strengthens a letter of medical necessity considerably. Access the ISSWSH process-of-care algorithm at PubMed.

"Bremelanotide and flibanserin are the only FDA-approved pharmacological options for HSDD in premenopausal women, and both have demonstrated efficacy in randomized controlled trials," per the ISSWSH 2019 process-of-care statement. Including that direct guideline language in a PA or appeal letter shows that the request aligns with recognized specialty society standards.

Quick Reference: UHC Vyleesi Coverage Checklist

Use this list before your prescriber submits the PA:

• Confirm HSDD diagnosis with validated scale scores (FSFI total at or below 26.55 or FSDS-DAO Item 13 score of 2 or higher)
• Verify premenopausal status is documented in the chart
• Document any reversible causes evaluated and ruled out
• Note flibanserin trial outcome (dates, doses, response) or specific contraindication
• Note any psychotherapy attended with dates
• Verify your UHC plan formulary tier and specific PA criteria at myuhc.com before submission
• Confirm manufacturer savings card eligibility if PA is pending or denied